{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:17:16Z","timestamp":1791346636320,"version":"4.3.1"},"reference-count":144,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2016M3A9B5942352"],"award-info":[{"award-number":["2016M3A9B5942352"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.jconrel.2021.02.018","type":"journal-article","created":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T18:14:35Z","timestamp":1614017675000},"page":"285-300","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Overcoming the barriers to optimization of adenovirus delivery using biomaterials: Current status and future perspective"],"prefix":"10.1016","volume":"332","author":[{"given":"Dayananda","family":"Kasala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JinWoo","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chae-Ok","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2021.02.018_bb0005","first-page":"798","article-title":"A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer","volume":"6","author":"Ganly","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0010","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/978-1-59745-561-9_35","article-title":"Phase I clinical trial of locoregional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomas","volume":"542","author":"Opyrchal","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0015","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.3015","article-title":"Gene therapy clinical trials worldwide to 2017: an update","volume":"20","author":"Ginn","year":"2018","journal-title":"J. Gene Med."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0020","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0025","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1517\/14712598.1.3.525","article-title":"Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials","volume":"1","author":"Kirn","year":"2001","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0030","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/ncponc0736","article-title":"Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress","volume":"4","author":"Liu","year":"2007","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0035","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.2174\/138920112800958904","article-title":"Recent clinical experience with oncolytic viruses","volume":"13","author":"Donnelly","year":"2012","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0040","doi-asserted-by":"crossref","first-page":"9130","DOI":"10.1128\/JVI.73.11.9130-9136.1999","article-title":"Construction of a pseudoreceptor that mediates transduction by adenoviruses expressing a ligand in fiber or penton base","volume":"73","author":"Einfeld","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0045","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.addr.2003.07.010","article-title":"Endocytosis of adenovirus and adenovirus capsid proteins","volume":"55","author":"Medina-Kauwe","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0050","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/978-1-62703-751-8_2","article-title":"Genetically engineering adenoviral vectors for gene therapy","volume":"1108","author":"Coughlan","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0055","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12033-007-0021-5","article-title":"Adenoviral vectors for gene therapy","volume":"36","author":"Douglas","year":"2007","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0060","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ymthe.2006.01.003","article-title":"Adenovirus type 5 interactions with human blood cells may compromise systemic delivery","volume":"14","author":"Lyons","year":"2006","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0065","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1182\/blood-2008-09-178459","article-title":"Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1","volume":"113","author":"Carlisle","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0070","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/cgt.2016.50","article-title":"Adenovirus coxsackie adenovirus receptor-mediated binding to human erythrocytes does not preclude systemic transduction","volume":"23","author":"Rojas","year":"2016","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0075","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines5030046","article-title":"Comparison of liver detargeting strategies for systemic therapy with oncolytic adenovirus serotype 5","volume":"5","author":"Nguyen","year":"2017","journal-title":"Biomedicines"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0080","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1089\/hum.1997.8.1-37","article-title":"Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration","volume":"8","author":"Worgall","year":"1997","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0085","doi-asserted-by":"crossref","first-page":"5896","DOI":"10.1158\/0008-5472.CAN-08-0488","article-title":"Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with oncolytic adenovirus","volume":"68","author":"Shashkova","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0090","doi-asserted-by":"crossref","first-page":"7478","DOI":"10.1128\/JVI.79.12.7478-7491.2005","article-title":"Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity","volume":"79","author":"Shayakhmetov","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0095","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1073\/pnas.0711757105","article-title":"Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo","volume":"105","author":"Kalyuzhniy","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0100","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.4161\/hv.29594","article-title":"Pre-existing immunity against ad vectors: humoral, cellular, and innate response, what\u2019s important?","volume":"10","author":"Fausther-Bovendo","year":"2014","journal-title":"Human Vaccin. Immunotherap."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0105","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/gt.2009.148","article-title":"Progress and prospects: immune responses to viral vectors","volume":"17","author":"Nayak","year":"2010","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0110","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1002\/1873-3468.13696","article-title":"Innate immunity to adenovirus: lessons from mice","volume":"593","author":"Atasheva","year":"2019","journal-title":"FEBS Lett."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0115","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1021\/mp100219n","article-title":"Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data","volume":"8","author":"Pesonen","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0120","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/jnci\/95.9.652","article-title":"Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway","volume":"95","author":"Fueyo","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0125","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2147\/OV.S196403","article-title":"Preclinical and clinical development of Oncolytic adenovirus for the treatment of malignant Glioma","volume":"8","author":"Kiyokawa","year":"2019","journal-title":"Oncolyt. Virother."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0130","doi-asserted-by":"crossref","DOI":"10.3390\/genes8020078","article-title":"Early insights from commercialization of gene therapies in Europe","volume":"8","author":"Touchot","year":"2017","journal-title":"Genes"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0135","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.addr.2011.12.011","article-title":"Evolution of oncolytic adenovirus for cancer treatment","volume":"64","author":"Choi","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0140","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.3892\/mmr.2016.5536","article-title":"Loss of coxsackie and adenovirus receptor expression in human colorectal cancer: a potential impact on the efficacy of adenovirus-mediated gene therapy in Chinese Han population","volume":"14","author":"Ma","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0145","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.urology.2005.02.033","article-title":"Loss of coxsackie and adenovirus receptor expression is associated with features of aggressive bladder cancer","volume":"66","author":"Matsumoto","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0150","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/sj.mt.6300321","article-title":"Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide","volume":"16","author":"Kreppel","year":"2008","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0155","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/mt.2011.112","article-title":"Tumor vascular targeted delivery of polymer-conjugated adenovirus vector for cancer gene therapy","volume":"19","author":"Yao","year":"2011","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0160","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.biomaterials.2010.10.031","article-title":"Active targeting and safety profile of PEG-modified adenovirus conjugated with herceptin","volume":"32","author":"Kim","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0165","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jconrel.2016.02.046","article-title":"Antitumor effect and safety profile of systemically delivered oncolytic adenovirus complexed with EGFR-targeted PAMAM-based dendrimer in orthotopic lung tumor model","volume":"231","author":"Yoon","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0170","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jviromet.2007.08.009","article-title":"A quantitative assay for measuring clearance of adenovirus vectors by Kupffer cells","volume":"147","author":"Smith","year":"2008","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0175","doi-asserted-by":"crossref","first-page":"11705","DOI":"10.1128\/JVI.01320-08","article-title":"Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement","volume":"82","author":"Xu","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0180","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1517\/17425247.5.4.385","article-title":"Polymers for viral gene delivery","volume":"5","author":"Wang","year":"2008","journal-title":"Exp. Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0185","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1016\/j.biomaterials.2011.11.020","article-title":"Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials","volume":"33","author":"Kim","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0190","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.actbio.2019.06.059","article-title":"Exploring the functions of polymers in adenovirus-mediated gene delivery: evading immune response and redirecting tropism","volume":"97","author":"Sun","year":"2019","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0195","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1517\/17425247.2014.874414","article-title":"Utilizing adenovirus vectors for gene delivery in cancer","volume":"11","author":"Kasala","year":"2014","journal-title":"Exp. Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0200","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jconrel.2015.10.009","article-title":"Polymeric oncolytic adenovirus for cancer gene therapy","volume":"219","author":"Choi","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0205","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.2217\/nnm-2016-0060","article-title":"Evolving lessons on nanomaterial-coated viral vectors for local and systemic gene therapy","volume":"11","author":"Kasala","year":"2016","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0210","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s11095-011-0629-9","article-title":"Magnetic nanoparticles enhance adenovirus transduction in vitro and in vivo","volume":"29","author":"Sapet","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0215","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/j.biomaterials.2008.12.015","article-title":"Direct cell entry of gold\/iron-oxide magnetic nanoparticles in adenovirus mediated gene delivery","volume":"30","author":"Kamei","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0220","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1021\/nl0500555","article-title":"Covalently linked Au nanoparticles to a viral vector: potential for combined photothermal and gene cancer therapy","volume":"6","author":"Everts","year":"2006","journal-title":"Nano Lett."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0225","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.tibtech.2009.01.003","article-title":"Designer adenoviruses for nanomedicine and nanodiagnostics","volume":"27","author":"Singh","year":"2009","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0230","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.addr.2009.12.003","article-title":"HPMA copolymers for masking and retargeting of therapeutic viruses","volume":"62","author":"Fisher","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0235","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1525-0016(02)00053-9","article-title":"Molecular weight-dependent gene transfection activity of unmodified and galactosylated polyethyleneimine on hepatoma cells and mouse liver","volume":"7","author":"Morimoto","year":"2003","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0240","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jconrel.2015.01.005","article-title":"pH-sensitive oncolytic adenovirus hybrid targeting acidic tumor microenvironment and angiogenesis","volume":"205","author":"Choi","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0245","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1021\/acs.bioconjchem.5b00357","article-title":"Tuning surface charge and PEGylation of biocompatible polymers for efficient delivery of nucleic acid or adenoviral vector","volume":"26","author":"Choi","year":"2015","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0250","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.bbrc.2014.03.142","article-title":"Polyethyleneimine-coating enhances adenoviral transduction of mesenchymal stem cells","volume":"447","author":"Yao","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0255","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1016\/j.biomaterials.2014.03.060","article-title":"Enhanced therapeutic efficacy of an adenovirus-PEI-bile-acid complex in tumors with low coxsackie and adenovirus receptor expression","volume":"35","author":"Lee","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0260","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jconrel.2009.11.001","article-title":"Physical adsorption of PEG grafted and blocked poly-L-lysine copolymers on adenovirus surface for enhanced gene transduction","volume":"142","author":"Park","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0265","doi-asserted-by":"crossref","first-page":"9536","DOI":"10.1016\/j.biomaterials.2011.08.069","article-title":"The transduction of Coxsackie and adenovirus receptor-negative cells and protection against neutralizing antibodies by HPMA-co-oligolysine copolymer-coated adenovirus","volume":"32","author":"Wang","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0270","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1021\/acs.biomac.5b00538","article-title":"Oncolytic adenovirus coated with multidegradable bioreducible Core-cross-linked Polyethylenimine for Cancer gene therapy","volume":"16","author":"Choi","year":"2015","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0275","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jconrel.2019.04.040","article-title":"Systemic administration of human mesenchymal stromal cells infected with polymer-coated oncolytic adenovirus induces efficient pancreatic tumor homing and infiltration","volume":"305","author":"Na","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0280","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1021\/bm501116x","article-title":"Safety profiles and antitumor efficacy of oncolytic adenovirus coated with bioreducible polymer in the treatment of a CAR negative tumor model","volume":"16","author":"Jung","year":"2015","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0285","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.biomaterials.2017.08.035","article-title":"Synergistic antitumor effect mediated by a paclitaxel-conjugated polymeric micelle-coated oncolytic adenovirus","volume":"145","author":"Kasala","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0290","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1016\/j.biomaterials.2013.03.004","article-title":"Therapeutic efficacy of a systemically delivered oncolytic adenovirus - biodegradable polymer complex","volume":"34","author":"Kim","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0295","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.2967\/jnumed.112.115493","article-title":"Systemic image-guided liver cancer radiovirotherapy using dendrimer-coated adenovirus encoding the sodium iodide symporter as theranostic gene","volume":"54","author":"Grunwald","year":"2013","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0300","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1016\/S0142-9612(02)00203-X","article-title":"Receptor-independent augmentation of adenovirus-mediated gene transfer with chitosan in vitro","volume":"23","author":"Kawamata","year":"2002","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0305","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1089\/hum.2011.014","article-title":"Gene therapy with recombinant adenovirus encoding endostatin encapsulated in cationic liposome in coxsackievirus and adenovirus receptor-deficient colon carcinoma murine models","volume":"22","author":"Wang","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0310","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1016\/j.biomaterials.2012.12.051","article-title":"Enzyme-responsive liposomes modified adenoviral vectors for enhanced tumor cell transduction and reduced immunogenicity","volume":"34","author":"Wan","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0315","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jconrel.2011.06.014","article-title":"Viral genome DNA\/lipoplexes elicit in situ oncolytic viral replication and potent antitumor efficacy via systemic delivery","volume":"155","author":"Kwon","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0320","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1021\/cr800409e","article-title":"Nonviral vectors for gene delivery","volume":"109","author":"Mintzer","year":"2009","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0325","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/(SICI)1097-4636(19990605)45:3<268::AID-JBM15>3.0.CO;2-Q","article-title":"Size matters: molecular weight affects the efficiency of poly(ethylenimine) as a gene delivery vehicle","volume":"45","author":"Godbey","year":"1999","journal-title":"J. Biomed. Mater. Res."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0330","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.2174\/1381612821666151027152907","article-title":"Polyethyleneimine-based Nanocarriers for gene delivery","volume":"21","author":"Wang","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0335","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jconrel.2015.01.004","article-title":"Development of porous PLGA\/PEI1.8k biodegradable microspheres for the delivery of mesenchymal stem cells (MSCs)","volume":"205","author":"Lee","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0340","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1182\/blood.V97.8.2221","article-title":"Systemic circulation of poly(L-lysine)\/DNA vectors is influenced by polycation molecular weight and type of DNA: differential circulation in mice and rats and the implications for human gene therapy","volume":"97","author":"Ward","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0345","doi-asserted-by":"crossref","first-page":"6479","DOI":"10.1074\/jbc.272.10.6479","article-title":"Complexes of adenovirus with polycationic polymers and cationic lipids increase the efficiency of gene transfer in vitro and in vivo","volume":"272","author":"Fasbender","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0350","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jconrel.2014.04.012","article-title":"Bioreducible polymers for therapeutic gene delivery","volume":"190","author":"Lee","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0355","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40824-019-0156-z","article-title":"Recent advances in the development of gene delivery systems","volume":"23","author":"Sung","year":"2019","journal-title":"Biomater. Res."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0360","doi-asserted-by":"crossref","first-page":"9187","DOI":"10.1016\/j.biomaterials.2014.07.027","article-title":"Synergistic effect of amino acids modified on dendrimer surface in gene delivery","volume":"35","author":"Wang","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0365","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1021\/cr500542t","article-title":"Surface-engineered dendrimers in gene delivery","volume":"115","author":"Yang","year":"2015","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0370","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.biomaterials.2008.10.009","article-title":"Arginine-grafted bioreducible poly(disulfide amine) for gene delivery systems","volume":"30","author":"Kim","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0375","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/j.biomaterials.2009.11.043","article-title":"The effect of surface modification of adenovirus with an arginine-grafted bioreducible polymer on transduction efficiency and immunogenicity in cancer gene therapy","volume":"31","author":"Kim","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0380","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.2174\/138920112800958814","article-title":"Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress","volume":"13","author":"Kaur","year":"2012","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0385","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2174\/1568009617666170222123406","article-title":"Emergence of ad-mediated combination therapy against Cancer: what to expect?","volume":"18","author":"Hong","year":"2018","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0390","doi-asserted-by":"crossref","first-page":"17680","DOI":"10.1021\/ja307290j","article-title":"Disulfide cross-linked low generation dendrimers with high gene transfection efficacy, low cytotoxicity, and low cost","volume":"134","author":"Liu","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0395","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.nano.2008.12.007","article-title":"Activated and non-activated PAMAM dendrimers for gene delivery in vitro and in vivo","volume":"5","author":"Navarro","year":"2009","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0400","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0405","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1089\/nat.2018.0721","article-title":"Lipid nanoparticles enabling gene therapies: from concepts to clinical utility","volume":"28","author":"Kulkarni","year":"2018","journal-title":"Nucleic Acid Therap."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0410","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1021\/bc900393r","article-title":"Transfection efficiency of cationic lipids with different hydrophobic domains in gene delivery","volume":"21","author":"Zhi","year":"2010","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0415","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.addr.2016.08.005","article-title":"The design of peptide-amphiphiles as functional ligands for liposomal anticancer drug and gene delivery","volume":"110-111","author":"Kuang","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0420","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1021\/bc700464m","article-title":"Enhanced intracellular delivery of quantum dot and adenovirus nanoparticles triggered by acidic pH via surface charge reversal","volume":"19","author":"Mok","year":"2008","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0425","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.biomaterials.2014.11.021","article-title":"Dual tumor targeting with pH-sensitive and bioreducible polymer-complexed oncolytic adenovirus","volume":"41","author":"Moon","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0430","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.actbio.2015.09.014","article-title":"Enhanced anti-tumor efficacy and safety profile of tumor microenvironment-responsive oncolytic adenovirus nanocomplex by systemic administration","volume":"28","author":"Choi","year":"2015","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0435","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1089\/10430349950018021","article-title":"PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo","volume":"10","author":"O\u2019Riordan","year":"1999","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0440","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ymthe.2005.03.006","article-title":"Combined genetic and chemical capsid modifications enable flexible and efficient de- and retargeting of adenovirus vectors","volume":"12","author":"Kreppel","year":"2005","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0445","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1038\/mt.2008.86","article-title":"Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression","volume":"16","author":"Hofherr","year":"2008","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0450","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/gt.2009.95","article-title":"Systemic administration of a PEGylated adenovirus vector with a cancer-specific promoter is effective in a mouse model of metastasis","volume":"16","author":"Yao","year":"2009","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0455","doi-asserted-by":"crossref","first-page":"9328","DOI":"10.1016\/j.biomaterials.2011.08.066","article-title":"Bioreducible polymer-conjugated oncolytic adenovirus for hepatoma-specific therapy via systemic administration","volume":"32","author":"Kim","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0460","doi-asserted-by":"crossref","first-page":"6288","DOI":"10.1002\/anie.200902672","article-title":"Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives","volume":"49","author":"Knop","year":"2010","journal-title":"Angew. Chem."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0465","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1021\/acsnano.6b06040","article-title":"Diverse applications of nanomedicine","volume":"11","author":"Pelaz","year":"2017","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0470","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1021\/acs.nanolett.9b03193","article-title":"MnCaCs-biomineralized Oncolytic virus for bimodal imaging-guided and synergistically enhanced anticancer therapy","volume":"19","author":"Huang","year":"2019","journal-title":"Nano Lett."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0475","doi-asserted-by":"crossref","first-page":"10533","DOI":"10.1021\/acsnano.6b06530","article-title":"Mild hyperthermia induced by gold Nanorod-mediated Plasmonic Photothermal therapy enhances transduction and replication of Oncolytic adenoviral gene delivery","volume":"10","author":"Jung","year":"2016","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0480","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1007\/s00330-002-1721-7","article-title":"Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications","volume":"13","author":"Reimer","year":"2003","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0485","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.2217\/nnm.12.109","article-title":"Magnetic nanoparticle-based approaches to locally target therapy and enhance tissue regeneration in vivo","volume":"7","author":"Sensenig","year":"2012","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0490","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.nano.2008.02.001","article-title":"N-hexanoyl chitosan-stabilized magnetic nanoparticles: enhancement of adenoviral-mediated gene expression both in vitro and in vivo","volume":"4","author":"Bhattarai","year":"2008","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0495","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.biomaterials.2011.09.028","article-title":"Effects of nanoparticle coatings on the activity of oncolytic adenovirus-magnetic nanoparticle complexes","volume":"33","author":"Tresilwised","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0500","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1021\/mp100123t","article-title":"Boosting oncolytic adenovirus potency with magnetic nanoparticles and magnetic force","volume":"7","author":"Tresilwised","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0505","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.biomaterials.2015.07.001","article-title":"Using a magnetic field to redirect an oncolytic adenovirus complexed with iron oxide augments gene therapy efficacy","volume":"65","author":"Choi","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0510","doi-asserted-by":"crossref","first-page":"809891","DOI":"10.1155\/2013\/809891","article-title":"Therapeutic doses of nonsteroidal anti-inflammatory drugs inhibit osteosarcoma MG-63 osteoblast-like cells maturation, viability, and biomineralization potential","volume":"2013","author":"De Luna-Bertos","year":"2013","journal-title":"TheScientificWorldJournal"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0515","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jconrel.2019.01.034","article-title":"Silica cloaking of adenovirus enhances gene delivery while reducing immunogenicity","volume":"297","author":"Sapre","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0520","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1126\/science.1214804","article-title":"Designing cell-compatible hydrogels for biomedical applications","volume":"336","author":"Seliktar","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0525","first-page":"149","article-title":"Cell encapsulation in biodegradable hydrogels for tissue engineering applications, tissue engineering","volume":"14","author":"Nicodemus","year":"2008","journal-title":"Part B Reviews"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0530","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jconrel.2017.03.028","article-title":"Optimized biodegradable polymeric reservoir-mediated local and sustained co-delivery of dendritic cells and oncolytic adenovirus co-expressing IL-12 and GM-CSF for cancer immunotherapy","volume":"259","author":"Oh","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0535","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/gt.2013.10","article-title":"Local sustained delivery of oncolytic adenovirus with injectable alginate gel for cancer virotherapy","volume":"20","author":"Choi","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0540","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.biomaterials.2017.09.009","article-title":"A hydrogel matrix prolongs persistence and promotes specific localization of an oncolytic adenovirus in a tumor by restricting nonspecific shedding and an antiviral immune response","volume":"147","author":"Jung","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0545","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1039\/C9BM00992B","article-title":"Physically crosslinked injectable hydrogels for long-term delivery of oncolytic adenoviruses for cancer treatment","volume":"7","author":"Le","year":"2019","journal-title":"Biomat. Sci."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0550","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nmat4474","article-title":"Supramolecular biomaterials","volume":"15","author":"Webber","year":"2016","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0555","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1021\/cr200157d","article-title":"Hydrogels for protein delivery","volume":"112","author":"Vermonden","year":"2012","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0560","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1517\/17425247.2015.989830","article-title":"Silk-elastin-like protein biomaterials for the controlled delivery of therapeutics","volume":"12","author":"Huang","year":"2015","journal-title":"Exp. Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0565","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0169-409X(97)00124-5","article-title":"Protein release from alginate matrices","volume":"31","author":"Wee","year":"1998","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0570","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ijpharm.2012.01.050","article-title":"Fabrication of cross-linked alginate beads using electrospraying for adenovirus delivery","volume":"427","author":"Park","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0575","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.it.2016.09.006","article-title":"Dendritic cells and Cancer immunity","volume":"37","author":"Gardner","year":"2016","journal-title":"Trends Immunol."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0580","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0585","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1039\/b802470g","article-title":"A cyclic RGD-coated peptide nanoribbon as a selective intracellular nanocarrier","volume":"6","author":"Lim","year":"2008","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0590","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1021\/bm300665u","article-title":"Optimization and internalization mechanisms of PEGylated adenovirus vector with targeting peptide for cancer gene therapy","volume":"13","author":"Yao","year":"2012","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0595","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jconrel.2007.08.002","article-title":"Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells","volume":"123","author":"Jung","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0600","doi-asserted-by":"crossref","first-page":"5158","DOI":"10.1016\/j.biomaterials.2011.03.084","article-title":"Active targeting of RGD-conjugated bioreducible polymer for delivery of oncolytic adenovirus expressing shRNA against IL-8 mRNA","volume":"32","author":"Kim","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0605","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.jconrel.2015.09.068","article-title":"Hepatoma targeting peptide conjugated bio-reducible polymer complexed with oncolytic adenovirus for cancer gene therapy","volume":"220","author":"Choi","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0610","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.jconrel.2015.10.015","article-title":"Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model","volume":"220","author":"Na","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0615","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1021\/mp300366f","article-title":"Adenoviral vectors coated with PAMAM dendrimer conjugates allow CAR independent virus uptake and targeting to the EGF receptor","volume":"10","author":"Vetter","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0620","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jconrel.2013.03.030","article-title":"Therapeutic targeting of chitosan-PEG-folate-complexed oncolytic adenovirus for active and systemic cancer gene therapy","volume":"169","author":"Kwon","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0625","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17122037","article-title":"Integrins in the spotlight of cancer","volume":"17","author":"Bianconi","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0630","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1016\/j.biomaterials.2013.12.086","article-title":"Targeted gene delivery by polyplex micelles with crowded PEG palisade and cRGD moiety for systemic treatment of pancreatic tumors","volume":"35","author":"Ge","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0635","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/cgt.2012.64","article-title":"A review of RGD-functionalized nonviral gene delivery vectors for cancer therapy","volume":"19","author":"Park","year":"2012","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0640","doi-asserted-by":"crossref","first-page":"13447","DOI":"10.3390\/ijms140713447","article-title":"The functions and applications of RGD in tumor therapy and tissue engineering","volume":"14","author":"Wang","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0645","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/10611860410001714162","article-title":"Chitosan-DNA nanoparticles: effect on DNA integrity, bacterial transformation and transfection efficiency","volume":"12","author":"Bozkir","year":"2004","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0650","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0168-3659(00)00361-8","article-title":"Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency","volume":"70","author":"Mao","year":"2001","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0655","article-title":"Chitosan modification of adenovirus to modify transfection efficiency in bovine corneal epithelial cells","volume":"5","author":"Wang","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0660","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1089\/hum.2015.019","article-title":"Efficient transduction of primary vascular cells by the rare adenovirus serotype 49 vector","volume":"26","author":"Dakin","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0665","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1128\/JVI.02696-06","article-title":"Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D","volume":"81","author":"Abbink","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0670","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0073313","article-title":"Low seroprevalent species D adenovirus vectors as influenza vaccines","volume":"8","author":"Weaver","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2021.02.018_bb0675","doi-asserted-by":"crossref","first-page":"9590","DOI":"10.1128\/JVI.00740-12","article-title":"Vaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in rhesus monkeys","volume":"86","author":"Teigler","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0680","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3389\/fimmu.2018.00335","article-title":"Seroprevalence of neutralizing antibodies against human adenovirus Type-5 and chimpanzee adenovirus Type-68 in Cancer patients","volume":"9","author":"Zhao","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0685","doi-asserted-by":"crossref","DOI":"10.1038\/mto.2015.21","article-title":"Evaluation of polymer shielding for adenovirus serotype 6 (Ad6) for systemic virotherapy against human prostate cancers","volume":"3","author":"Nguyen","year":"2016","journal-title":"Mol. Ther. Oncolyt."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0690","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1089\/hum.2009.028","article-title":"Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus","volume":"20","author":"Doronin","year":"2009","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0695","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1021\/acs.bioconjchem.9b00189","article-title":"Polyvalent diazonium polymers provide efficient protection of oncolytic adenovirus enadenotucirev from neutralizing antibodies while maintaining biological activity in vitro and in vivo","volume":"30","author":"Francini","year":"2019","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0700","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3389\/fbioe.2019.00261","article-title":"Hazard assessment of polymeric Nanobiomaterials for drug delivery: what can we learn from literature so far","volume":"7","author":"Jesus","year":"2019","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0705","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1039\/C1CS15188F","article-title":"Toxicity of nanomaterials","volume":"41","author":"Sharifi","year":"2012","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0710","doi-asserted-by":"crossref","first-page":"16023","DOI":"10.1038\/mtm.2016.23","article-title":"Production and clinical development of nanoparticles for gene delivery, molecular therapy","volume":"3","author":"Chen","year":"2016","journal-title":"Methods Clin. Dev."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0715","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ygyno.2014.03.571","article-title":"A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group study","volume":"133","author":"Alvarez","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.jconrel.2021.02.018_bb0720","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.01.002","article-title":"Nanocarrier Vaccines for SARS-CoV-2","author":"Machhi","year":"2021","journal-title":"Adv. Drug Deliv. Rev."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365921000833?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365921000833?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:56:52Z","timestamp":1759161412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365921000833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":144,"alternative-id":["S0168365921000833"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2021.02.018","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming the barriers to optimization of adenovirus delivery using biomaterials: Current status and future perspective","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2021.02.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}